Loading...
Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been pu...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Dove Medical Press
2010
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2915536/ https://ncbi.nlm.nih.gov/pubmed/20689698 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|